Who are Azelex's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Avodart, Finacea, Avodart, Gamolenic.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/azelaic-acid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Azelex — Competitive Intelligence Brief

Azelex (AZELAIC ACID) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: azelaic acid. Area: Dermatology.

marketed azelaic acid 3-oxo-5-alpha-steroid 4-dehydrogenase 2 Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Azelex (AZELAIC ACID) — Leo Pharma As. Azelex works by inhibiting the enzyme 3-oxo-5-alpha-steroid 4-dehydrogenase 2, which is involved in the production of androgens that contribute to acne and rosacea.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Azelex TARGET	AZELAIC ACID	Leo Pharma As	marketed	azelaic acid	3-oxo-5-alpha-steroid 4-dehydrogenase 2	1995-01-01
Avodart	dutasteride	GSK (GlaxoSmithKline)	marketed	5-alpha-reductase inhibitor (dual)	3-oxo-5-alpha-steroid 4-dehydrogenase 1, 3-oxo-5-alpha-steroid 4-dehydrogenase 2, Glycine receptor subunit alpha-1	2001-11-20
Finacea	Finacea	Actavis Inc.	marketed		3-oxo-5-alpha-steroid 4-dehydrogenase 2
Avodart	Avodart	GlaxoSmithKline	marketed		3-oxo-5-alpha-steroid 4-dehydrogenase 1, 3-oxo-5-alpha-steroid 4-dehydrogenase 2, Glycine receptor subunit alpha-1
Gamolenic	GAMOLENIC ACID		marketed	gamolenic acid	Free fatty acid receptor 1, Peroxisome proliferator-activated receptor delta, 3-oxo-5-alpha-steroid 4-dehydrogenase 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-09-18 — Azelex · 7700076 · Formulation · US
2027-10-18 — Azelex · 10117812 · Formulation · US
2027-12-08 — Azelex · 9265725 · Formulation · US
2029-02-28 — Azelex · 9211259 · Method of Use · US

Sponsor landscape (azelaic acid class)

Leo Pharma As · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Azelex — Competitive Intelligence Brief. https://druglandscape.com/ci/azelaic-acid. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab